| [1] |
江多斯•帕依孜吾拉，吐尔洪江•吐逊，李涛，等．TSP-1和TGF-β在肝切除术后肝衰竭预测中的价值[J/CD]．中华肝脏外科手术学电子杂志，2019, 8(2):149-153.
|
| [2] |
Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth[J]. J Cell Mol Med, 2002, 6(1):1-12.
|
| [3] |
Azcutia V, Routledge M, Williams MR, et al. CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions[J]. Mol Biol Cell, 2013, 24(21):3358-3368.
|
| [4] |
Hayat SMG, Bianconi V, Pirro M, et al. CD47: role in the immune system and application to cancer therapy[J]. Cell Oncol, 2020, 43(1): 19-30.
|
| [5] |
Folkes AS, Feng M, Zain JM, et al. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma exp-erience[J].Curr Opin Oncol, 2018, 30(5):332-337.
|
| [6] |
Poon RT, Chung KK, Cheung ST, et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 10(12 Pt 1):4150-4157.
|
| [7] |
Tao Y, Wang M, Chen E, et al. Liver regeneration: analysis of the main relevant signaling molecules[J]. Mediators Inflamm, 2017: 4256352.
|
| [8] |
Starlinger P, Assinger A, Haegele S, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans[J]. Hepatology, 2014, 60(1):257-266.
|
| [9] |
Starlinger P, Pereyra D, Haegele S, et al. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection[J]. Hepatology, 2018, 67(4): 1516-1530.
|
| [10] |
Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration[J]. World J Gastroenterol, 2017, 23(18):3228-3239.
|
| [11] |
Starlinger P, Haegele S, Wanek D, et al. Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction[J]. Br J Surg, 2015, 102(7):826-836.
|
| [12] |
Starlinger P, Schauer D, Alidzanovic L, et al. Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration[J]. J Hepatol, 2013, 58(5):1053-1054.
|
| [13] |
Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation:a therapeutic target for fibrotic disease[J]. Matrix Biol, 2018(68/69):28-43.
|
| [14] |
刘怡菲，刘先哲．转化生长因子的活化调节[J]．实用医学杂志，2011, 27(22):4166-4168.
|
| [15] |
Hayashi H, Sakai K, Baba H, et al. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice[J]. Hepatology, 2012, 55(5):1562-1573.
|
| [16] |
Davoodian P, Ravanshad M, Hosseini SY, et al. Effect of TGF-beta/smad signaling pathway blocking on expression profiles of miR-335, miR-150, miR-194, miR-27a, and miR-199a of hepatic stellate cells (HSCs)[J]. Gastroenterol Hepatol Bed Bench, 2017, 10(2):112-117.
|
| [17] |
Jiang N, Zhang Z, Shao X, et al. Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-β1/Smad3 signaling pathway[J]. J Cell Physiol, 2020, 235(1):364-379.
|
| [18] |
Krishna SM, Seto SW, Jose RJ, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotension II-infused apolipoprotein-E-deficient mouse[J]. Arterioscler Thromb Vasc Biol, 2015, 35(2):389-398.
|
| [19] |
Nakamura T, Ueno T, Sakamoto M, et al. Suppression of transforming growth factor-b results in upregulation of transcript-ion of regeneration factors after chronic liver injury[J]. J Hepatol, 2004, 41(6):974-982.
|
| [20] |
Oe S, Lemmer ER, Conner EA, et al. Intact signaling by transforming growth factor is not required for termination of liver regeneration in mice [J]. Hepatology, 2004, 40(5):1098-1105.
|
| [21] |
Gao Q, Chen K, Gao L, et al. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells[J]. Cell Death Dis, 2016, 7(9):e2368.
|
| [22] |
Jiménez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1[J]. Nat Med, 2000, 6(1):41-48.
|
| [23] |
Isenberg JS, Frazier WA, Krishna MC, et al. Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling[J]. Curr Drug Targets, 2008, 9(10):833-841.
|
| [24] |
Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vas-cular homeostasis[J]. Cell, 2007, 130(4):69l-703.
|
| [25] |
Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2[J]. Cold Spring Harb Perspect Med, 2012, 2(5):a006627.
|
| [26] |
Kaur S, Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2[J]. Cell Cycle, 2011, 10(1):10-12.
|
| [27] |
Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1[J]. FASEB J, 1996, 10(10):1183-1191.
|
| [28] |
Vogel T, Guo NH, Krutzsch HC, et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin[J]. J Cell Biochem, 1993, 53(1):74-84.
|
| [29] |
Bagavandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin[J]. Biochem Biophys Res Commun, 1990, 170(2):867-872.
|
| [30] |
Phelan MW, Forman LW, Perrine SP, et al. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells[J]. J Lab Clin Med, 1998, 132(6):519-529.
|
| [31] |
Isenberg JS, Roberts DD. The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury[J]. Pediatr Nephrol, 2019, 34(12):2479-2494.
|
| [32] |
Isenberg JS, Maxhimer JB, Powers P, et al. Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling[J]. Surgery, 2008, 144(5):752-761.
|
| [33] |
Maxhimer JB, Shih HB, Isenberg JS, et al. Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective[J]. Plast Reconstr Surg, 2009, 124(6): 1880-1889.
|
| [34] |
Xiao Z, Banan B, Xu M, et al. Attenuation of ischemia-reperfusion injury and improvement of survival in recipients of steatotic cat livers using CD47 monoclonal antibody[J]. Transplantation, 2016, 100(7):1480-1489.
|